Combinostics, founded in 2014, offers the cNeuro™ platform, which combines the company’s innovative AI technology with a holistic view of patient data—including imaging biomarkers, demographic and clinical information, neuropsychology test results, and other biomarkers. This comprehensive approach enables clinicians to make reliable, evidence-based diagnostic and management decisions for patients with neurological disorders.